Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
UCB |
---|---|
Information provided by: | UCB |
ClinicalTrials.gov Identifier: | NCT00643500 |
Patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study
Condition | Intervention | Phase |
---|---|---|
Epilepsy, Partial |
Drug: Levetiracetam |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | UCB ( Study Director ) |
Study ID Numbers: | N01033 |
Study First Received: | February 21, 2008 |
Last Updated: | March 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00643500 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Levetiracetam Keppra |
Epilepsies, Partial Nootropic Agents Epilepsy Central Nervous System Diseases |
Etiracetam Brain Diseases Anticonvulsants |
Epilepsies, Partial Nootropic Agents Epilepsy Therapeutic Uses Nervous System Diseases Central Nervous System Diseases |
Etiracetam Brain Diseases Central Nervous System Agents Pharmacologic Actions Anticonvulsants |